Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C

Kanda, 2016, Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan, Int J Med Sci, 13, 418, 10.7150/ijms.15519 Suzuki, 2018, Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan, Hepatol Int, 12, 244, 10.1007/s12072-018-9872-z Tsuji, 2018, Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group, J Gastroenterol, 53, 1142, 10.1007/s00535-018-1455-1 Kumada, 2015, Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for HCV genotype 1b-infected Japanese patients with or without cirrhosis, Hepatology, 62, 1037, 10.1002/hep.27972 Kumada, 2017, The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study, J Gastroenterol, 52, 520, 10.1007/s00535-016-1285-y Toyota, 2017, Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection, J Gastroenterol, 52, 385, 10.1007/s00535-016-1245-6 Chayama, 2018, Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis, J Gastroenterol, 53, 557, 10.1007/s00535-017-1391-5 Younossi, 2016, Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial, J Hepatol, 65, 33, 10.1016/j.jhep.2016.02.042 Itakura, 2016, Complex pattern of resistance-associated substitutions of hepatitis C virus after daclatasvir/asunaprevir treatment failure, PLoS One, 11, e0165339, 10.1371/journal.pone.0165339 Zeuzem, 2017, NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome, J Hepatol, 66, 910, 10.1016/j.jhep.2017.01.007 Uchida, 2018, Significance of NS5B substitutions in genotype 1b hepatitis C virus evaluated by bioinformatics analysis, Sci Rep, 8, 8818, 10.1038/s41598-018-27291-7 Krishnan, 2015, Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir-ritonavir and ombitasvir, Antimicrob Agents Chemother, 60, 1106, 10.1128/AAC.02606-15 Zeuzem, 2018, The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection, J Gastroenterol, 53, 679, 10.1007/s00535-018-1429-3 McPhee, 2018, Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir, Antivir Ther, 23, 53, 10.3851/IMP3177 Teraoka, 2018, Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, J Gen Virol, 99, 1058, 10.1099/jgv.0.001091 Dietz, 2018, Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals, Gastroenterology, 154, 976, 10.1053/j.gastro.2017.11.007 Nitta, 2019, Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients, Sci Rep, 9, 5722, 10.1038/s41598-019-42114-z Krishnan, 2018, Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan, Antimicrob Agents Chemother, 62, 10.1128/AAC.01249-18 Mawatari, 2018, The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in hepatitis C virus genotype 1 patients treated with sofosbuvir and ledipasvir, PLoS One, 13, e0198642, 10.1371/journal.pone.0198642 Pawlotsky, 2016, Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens, Gastroenterology, 151, 70, 10.1053/j.gastro.2016.04.003 Kanda, 2013, Investigation of the freely available easy-to-use software “EZR” for medical statistics, Bone Marrow Transpl, 48, 452, 10.1038/bmt.2012.244 Lontok, 2015, Hepatitis C virus drug resistance-associated substitutions: state of the art summary, Hepatology, 62, 1623, 10.1002/hep.27934 Pelosi, 2012, Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir, Antimicrob Agents Chemother, 56, 5230, 10.1128/AAC.01209-12 Uemura, 2019, NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir, J Gastroenterol, 54, 459, 10.1007/s00535-018-01543-9 Kumada, 2018, Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection, J Gastroenterol, 53, 566, 10.1007/s00535-017-1396-0 Poordad, 2018, Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure, Hepatology, 67, 1253, 10.1002/hep.29671 Sarrazin, 2016, The importance of resistance to direct antiviral drugs in HCV infection in clinical practice, J Hepatol, 64, 486, 10.1016/j.jhep.2015.09.011 Jeong, 2018, Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures, J Viral Hepat, 25, 1251, 10.1111/jvh.12932 Itakura, 2015, Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy, Hepatol Res, 45, E115, 10.1111/hepr.12474